

Peer Review File

Article information: <https://dx.doi.org/10.21037/jtd-23-1858>

Reviewer A

The authors submit a protocol to determine the efficacy of 3rd line treatment for patients with advanced non-small cell lung cancer (NSCLC). To assess efficacy, they have designed a single-arm study, investigator-initiated phase II study is designed to evaluate combination treatment of nivolumab and TM5614, a plasminogen activator inhibitor (PAI)-1.

I believe that the authors start from an interesting approach, with an adequate design to be able to respond to the questions raised.

I believe that the recruitment period may be long given the prevalence of the pathology, a fact that will delay results that could be good for patients.

Reply

We thank the reviewer for the pertinent comment. Currently, the enrollment period for our clinical trial has reached 6 months. We have been able to enroll 80% of the planned number of cases each month. Recently, the number of potential cases for trial participation has increased at the participating facilities. Therefore, an increase in the number of enrollments per month is expected going forward. Although there may be concerns about enrollment delays, as reviewers have mentioned, we believe that we can complete the enrollment within the 16-month registration period.

Reviewer B

The study is promising. I am looking forward to your results to come.

Reply

Thank you very much for reviewing our paper.